Core Scientific's 108.8% YoY revenue growth to $164.2M in 2026Q2 reflects a strategic pivot toward high-growth AI/HPC infrastructure, yet this expansion is financed by a debt-fueled balance sheet that has driven total debt to $4.3B and equity to -$2.4B. Gross ...
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue rebounded 108.8% YoY to $164.2M in 2026Q2 with gross margin recovering to 42.7%, but operating income swung to -$72.1M and net income to -$1.2B, reflecting extreme earnings volatility.
Core Scientific's forward P/E ratio of 29.15 and forward PS ratio of 8.20 suggest it is fairly valued compared to historical averages, with a fair price range estimated between $15.81 to $28.27.
Core Scientific is repurposing its Pecos, Texas site into a 1.5 gigawatt AI-focused data center campus, supported by a $3.30 billion notes offering, signaling strong growth in AI infrastructure.
Expanded institutional interest and long-term AI infrastructure partnerships highlight Core Scientific's potential as a key player in the AI and data center space.
Trailing total returns as of 9/23/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Jul 28, 2026 | -$3.32-5201.8% vs -$0.06 | $164M+16.4% vs $141M |
Q2 2026 May 6, 2026 | -$1.06-5200.0% vs -$0.02 | $115M-1.5% vs $117M |
Q2 2026 Mar 2, 2026 | -$0.42-156.8% vs -$0.16 | $80M-33.0% vs $119M |
Q4 2025 Oct 24, 2025 | -$0.46-558.9% vs -$0.07 | $81M-27.6% vs $112M |
Core Scientific, Inc. (NASDAQ: CORZ - Get Free Report) Director Eric Weiss bought 6,000 shares of the company's stock in a transaction on Tuesday, September 15th. The stock was bought at an average cost of $16.33 per share, with a total value of $97,980.00. Following the completion of the purchase, the director owned 265,262 shares of
TeraWulf (NASDAQ:WULF) shares are running higher on Wednesday as buying returns to a narrow group of Bitcoin miners that have pivoted their platforms toward artificial intelligence hosting. The stock is up 7% to $15.
Shares of Cipher Mining (NASDAQ:CIFR) are up 9% to $16.42 in early Wednesday trading after the Electric Reliability Council of Texas (ERCOT) disclosed conditional grid capacity covering 3.2 gigawatts across Cipher's Texas projects.
For years, bitcoin miners traded like a leveraged bet on the token they produce. That relationship broke down over the past year, according to a recent CoinShares report.
Benchmark CORZ against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Core Scientific, Inc. (CORZ)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $18.79 | $6.04B | -21.35 | -37.53% | -90.47% | — | — | |
| $24.93 | $9.43B | -12.78 | 66.36% | -196.28% | -48.36% | — | |
| $13.63 | $5.2B | -3.69 | 33.47% | -429.71% | -125.83% | — | |
| $15.14 | $3.89B | 13.52 | 102.21% | -146.9% | -75.24% | — | |
| $19.09 | $7.81B | -8.88 | 25.29% | -3663.46% | -151.95% | — | |
| $1.86 | $651.03M | -6.00 | -32.54% | -5.6% | -38.19% | — |
Core Scientific, Inc. (CORZ) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Core Scientific, Inc. (CORZ) SEC filings — annual & quarterly reports (10-K, 10-Q)
Jul 29, 2026·SEC
Jul 28, 2026·SEC
Jul 28, 2026·SEC
Get notified when CORZ posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Core Scientific, Inc. (CORZ) stock FAQ — growth, dividends, profitability & financials explained
Core Scientific, Inc. (CORZ) reported $440.3M in revenue for fiscal year 2025. This represents a 640% increase from $59.5M in 2019.
Core Scientific, Inc. (CORZ) saw revenue decline by 37.5% over the past year.
Core Scientific, Inc. (CORZ) reported a net loss of $1.44B for fiscal year 2025.
Core Scientific, Inc. (CORZ) had negative free cash flow of $967.9M in fiscal year 2025, likely due to heavy capital investments.
